Eisler Capital (Us) LLC Ascendis Pharma A/S Transaction History
Eisler Capital (Us) LLC
- $5.6 Trillion
- Q2 2024
A detailed history of Eisler Capital (Us) LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Eisler Capital (Us) LLC holds 6,080 shares of ASND stock, worth $724,918. This represents 0.01% of its overall portfolio holdings.
Number of Shares
6,080Holding current value
$724,918% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding ASND
# of Institutions
223Shares Held
56.5MCall Options Held
142KPut Options Held
259K-
Ra Capital Management, L.P. Boston, MA10.1MShares$1.21 Billion20.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA4.96MShares$592 Million3.41% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.3MShares$512 Million0.93% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.2MShares$500 Million7.81% of portfolio
-
Janus Henderson Group PLC London, X03.92MShares$467 Million0.29% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $6.65B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...